Summit Therapeutics
A UK-based, clinical-stage drug discovery and development company.
It is conducting clinical programs focused on oncologicals and anti-infectives.
In December 2022, Summit announced a licensing deal with a Chinese drug developer that could cost it as much as $5 billion. Summit will in-license Akeso’s (9926.HK) breakthrough bispecific antibody, ivonescimab.
Latest Summit Therapeutics News & Features
23 January 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze